A child’s mind is no place for migraines
As you know, migraine attacks can interfere with a person’s everyday life. And migraines in children can look differently from migraines in adults. This is why we wanted to make you aware of a research opportunity that you may be interested in for your child.
Lilly is currently enrolling participants for multiple migraine research studies for children and teens ages 6 to 17, and your child may be able to take part. These studies are evaluating the safety and effectiveness of investigational medications that are already approved for the treatment of migraine in adults. The studies in this program include:
- PIONEER-PEDS-1: A study in children and teens for the acute treatment of episodic migraine
- REBUILD-1: A study in children and teens for the preventive treatment of episodic migraine
- REBUILD-2: A study in children and teens for the preventive treatment of chronic migraine
You don’t need to know which studies are available in your area or choose one now. To learn more about eligibility for these studies and clinical research in general, we invite you to visit the program’s website.
Thank you for considering these important migraine research studies.
Pediatric Migraine Clinical Trial
Biohaven Pharmaceuticals is studying an investigational drug, called rimegepant, for the acute treatment of migraines in the pediatric population. If your child is between 12 and 17 years of age and has at least a 6-month history of migraine, they may qualify. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.